Do we need to use nitric oxide in preterm babies in developing countries?

Pankaj Garg¹

Abstract

Neonatal care in developing nations is advancing rapidly. There is an increasing tendency to include nitric oxide in the therapeutic armamentarium. But the opinion regarding its use remains divided among neonatologists even in the western world [1]. Nitric oxide has an established role in the management of persistent pulmonary hypertension in term neonates. However, the use of nitric oxide in preterm neonates has been controversial and the Cochrane review updated in 2001 did not give conclusive answers. There have been adequately powered multi-centre trials recently on the issue, planned to resolve the controversy. The present communication highlights the salient features and conclusions drawn from these trials.

The survival of preterm and extremely low birthweight neonates has increased dramatically [2]. There have been dramatic responses to exogenous surfactant treatment. However, a subset of these neonates with hyaline membrane disease may have suboptimal response because of severe pulmonary hypertension [3,4]. Inhaled nitric oxide may be beneficial for them by dilating the pulmonary vasculature, improving ventilation/perfusion mismatch, and decreasing the pulmonary inflammatory response [5,6]. Inhaled nitric oxide has an established role for the management of persistent pulmonary hypertension in term neonates [7]. Its role in preterm neonates has been controversial and its safety and efficacy have been questioned [8,9]. Meta-analysis of randomised trials done up to 1999 did not give conclusive answers [10]. Studies done in the past were underpowered and had methodological limitations such as entry criteria, drug concentration, and duration and definition of response. To resolve this controversy recent randomised trials have been conducted. I searched the MEDLINE (PubMed), CINAHL, EMBASE, Cochrane-controlled trials and did a hand-search of major paediatric and neonatology journals for randomised trials pertaining to the use of inhaled nitric oxide in preterm neonates from 1996 onwards. This communication discusses three recently concluded large multi-centric trials and summarises the results of other randomised trials:

1. Preemie Inhaled Nitric Oxide Group (USA): This was a multi-centre, randomised, blinded controlled trial from 16 centres of the National Institute of Child Health and Human Development (NICHD) Neonatal Research Network [11]. A dedicated telephone system was used for randomisation. Infants were stratified according to the centre and birthweight using a permuted block design method. The primary hypothesis was that administration of inhaled nitric oxide would reduce the incidence of bronchopulmonary dysplasia (BPD) or death in neonates less than 34 weeks gestation and birthweight between 401–1500 g. The group recruited 420 infants less than 34 weeks (401–1500 g; 47% < 750 g) at 4–120 hours of age with oxygenation index ≥5 followed by 7.5 and having received at least one dose of surfactant 4 hours before meeting the criteria. The study was terminated when two thirds of the infants reached study end-points of death, discharge or 1 year corrected age due to higher incidence of intraventricular haemorrhage (IVH) noted in the inhaled nitric oxide (iNO) group at interim analysis. Infants were randomised to receive 5 ppm iNO or simulated flow by an unblinded respiratory therapist with concentration increased to maximum of 10 ppm if there was a partial response (PaO₂ increases between 10–20 mm Hg). The study gas was weaned after 10–14 hours if PaO₂ was > 50 mmHg and saturation was more than 90%. The maximum duration the gas could be given was 14 days (concentration limited to ≤ 1 ppm if given for > 10 days).

Safety monitoring was ensured by using frequent measurement of methaemoglobin concentrations and continuous nitrogen dioxide measurements. Both the study and control groups were comparable in terms of baseline characteristics (mean weight 840g, mean gestational age 26 weeks, about 70% antenatal steroid use) and status at the time of randomisation (mean age 26 hours, mean oxygenation index 23). There was no difference for either primary or secondary outcomes between the groups. The incidence of BPD or death was 80% in the iNO group versus 82% in the placebo group (relative risk, RR 0.97; 95% CI 0.86–1.08; p = 0.26). Similarly, there was no difference for severe IVH, oxygen use, physiological BPD, length of hospitalisation, duration of ventilation, air leaks and threshold retinopathy of prematurity. There was a short term improvement in oxygenation in the iNO group with 5 ppm which does not persist with doubling of the dose. However, post hoc analysis after stratification of birthweight (<1000 g and >1000 g), type of ventilation and oxygenation index (OI) for severity of illness (OI < 17, or OI > 17) revealed some striking findings. In the birthweight category <1000 g death or severe IVH was more in the group given iNO (62% vs 48%, RR 1.28, 95% CI 1.06–1.54; P = 0.01; 43% vs 33%, RR 1.40, 95% CI 1.03–1.88; P = 0.03 respectively). Infants >1000 g had

¹Neonatal Registrar, Royal Hospital for Women, University of New South Wales, Randwick, NSW, Australia, 2031; e-mail: <GargP@sesiabs.nsw.gov.au>, <pankajparul8@rediffmail.com>. (Conflict of interest: none declared).
lower rates of death or BPD (50% vs 69%; RR 0.72, 95% CI 0.54–0.96; P = 0.03).

The findings from this well conducted high quality study show that (a) iNO does not alter the mortality or morbidity profile of preterm <1500 g and <34 weeks’ gestation, (b) increase in the incidence of IVH in infants <1000 g may reflect production of biologically toxic by-products and indicates caution for use in this group. However, it is not clear from the study whether IVH occurred prior to exposure of iNO or after it as Ultrasound cranium was done at 28±3 days in the study, and (c) doubling the dose of inhaled nitric oxide to 10 ppm does not offer any advantage even in short terms.

2. INNOVA Multi-centre Trial (the UK and the Republic of Ireland): This trial was conducted in 15 neonatal units of the UK and the Republic of Ireland [12]. The study could only recruit just over half of its recruitment target (108 infants as against an expected sample size of 200 needed to power the study). The main reason given for this was physician characteristics, as many clinicians were convinced regarding the perceived benefits of iNO (75 eligible preterm received nitric oxide outside the study trial). Infants <34 weeks gestation and less than 28 days requiring ventilation were randomised to receive either iNO starting from 5 ppm increased to a maximum of 10 ppm. Mean gestational age was about 25.7 weeks and 31% infants were <1000 g. Mean oxygenation index was 14.6 for iNO versus 12 for controls. The major caveats of this trial was the use of an open label iNO in newborns with refractory hypoxaemia (PaO2 <50% on 100% oxygen) as per the ruling of the French drug authority law, which recommends iNO use in any newborn with refractory hypoxaemia (20 eligible infants at <6 hours of age, 20 in iNO group and 28 of control group). This decreased the power of the study.

To establish the safety of inhaled nitric oxide the authors used multivariate stepwise logistic regression analysis and evaluated the risk factors of IVH, brain lesions (IVH or periventricular leucomalacia, PVL) or death and BPD at 28 days of life. Nitric oxide therapy was included in all models. There were no differences in primary outcome defined as intact survival at 28 days (61.4% iNO vs 61.1%; p = 0.943). There were no differences in secondary outcomes also (necrotising enterocolitis 8% vs 6%, patent ductus arteriosus 34% vs 37%, mortality 41% vs 31% and infants with respiratory support on day 28 44% vs 47% between iNO groups and controls respectively). No differences were established for the occurrence of IVH before onset of nitric oxide or on day 7 of life. Inhaled nitric oxide was not an independent risk factor for the combined risk of death or brain lesions (adjusted RR 1.29, 95% CI 0.796–2.12) and BPD (adjusted RR 0.653; 95% CI 0.403–1.057). In fact, 45% of infants receiving iNO had a positive response (defined as increase in a/A >0.22).

The study concluded that inhaled nitric oxide is safe in preterm neonates but did not affect outcomes. To further substantiate the safety of inhaled nitric oxide in the same group of neonates in another parallel study, the authors also assessed malondialdehyde (MDA) concentrations as an oxidative stress marker and total plasmatic glutathione (GSH), intraerythrocyte GSH peroxidase and GSH reductase activities as antioxidant defenses. After 24 hours the rise of MDA was blunted in the iNO group. Conversely, GSH was more stable in the iNO group. On day 28 oxygen dependence was linked with a higher...
### Table 1. Highlights of the randomised controlled trial using iNO for preterm neonates

<table>
<thead>
<tr>
<th>Study</th>
<th>No. of babies</th>
<th>GA(weeks) &amp; mean-weight</th>
<th>Age at randomisation(hours)</th>
<th>iNO dose (ppm)</th>
<th>Entry criteria</th>
<th>Definition of response</th>
<th>Primary end points</th>
<th>Cranial USG</th>
<th>Conclusions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preemie iNO study group [11]</td>
<td>420</td>
<td>&lt;34, 840 g</td>
<td>26</td>
<td>10</td>
<td>Ventilated received one dose of surfactant, OI &gt;5/lb &gt;7.</td>
<td>PaO₂ increase &gt;20 mmHg</td>
<td>Death or BPD, discharge or 1 year corrected age</td>
<td>28±3 days</td>
<td>No effect on outcomes, &lt;1000 g ↑ in severe IVH or PVL</td>
</tr>
<tr>
<td>INNOVA trial [12]</td>
<td>108</td>
<td>&lt;34, 1060 g</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Weekly</td>
<td>No evidence of effect, ↑ time on ventilator or hospital and mean costs</td>
</tr>
<tr>
<td>Franco-Belgium group [13]</td>
<td>860</td>
<td>&lt;32, 31%, &lt;1000 g</td>
<td>14</td>
<td>10</td>
<td>GA &lt;32 weeks and ventilated</td>
<td>PaO₂ &gt;22.5 mmHg after 15 min</td>
<td>Death or severe disability at 1 year corrected age or death before d/s or CLD</td>
<td>Weekly</td>
<td>iNO not an independent risk factor for BPD or death or brain lesions, no effect on outcome</td>
</tr>
<tr>
<td>Schreiber et al. [15]</td>
<td>207</td>
<td>&lt;34, 1017 g</td>
<td>&lt;72 (12-24)</td>
<td>10</td>
<td>RDS ventilated and received surfactant</td>
<td>—</td>
<td>Death or CLD</td>
<td>Weekly</td>
<td>iNO decreases incidence of death or CLD and ↓ incidence of IVH or PVL</td>
</tr>
<tr>
<td>Subbedar et al. [17]</td>
<td>42</td>
<td>≤32 weeks, 882</td>
<td>96</td>
<td>20</td>
<td>Ventilated for RDS since birth</td>
<td>↓ in OI of ≤25% or reduction in FiO₂ of ≤0.10</td>
<td>Death, CLD, CLD or death</td>
<td>Weekly</td>
<td>No effect on outcome</td>
</tr>
<tr>
<td>Kinsella et al. [18]</td>
<td>80</td>
<td>≤34, 1040</td>
<td>Controls 27 h, iNO 30 h</td>
<td>5</td>
<td>Severe hypoxaemia a/A ≤0.10</td>
<td>—</td>
<td>Survival to discharge</td>
<td>At study entry and D7</td>
<td>No effect on adverse events or outcome</td>
</tr>
<tr>
<td>Mercier et al. [19]</td>
<td>85</td>
<td>≤33, 1150</td>
<td>Controls 1d, iNO 0 d</td>
<td>20</td>
<td>OI 12.5–30</td>
<td>≥33% ↓ OI</td>
<td>OI at 2 hours after start</td>
<td>Prior to randomisation</td>
<td>Improves oxygenation &amp; ↓ length of stay</td>
</tr>
</tbody>
</table>

ALI = Acute lung injury, a/A = arterial-alveolar ratio, BPD = bronchopulmonary dysplasia, CLD = chronic lung disease, GA = gestational age, INNOVA = multicentric trial of Premie inhaled NO group, iNO = inhaled nitric oxide, IVH = intraventricular haemorrhage, OI = oxygenation index, RDS = respiratory distress syndrome.
increase in MDA as was the risk of death, whereas IVH was associated with a higher initial drop in GSH. The study showed that early low dose iNO in hypoxaemic preterm neonates improves oxidative balance, and seems to be clinically beneficial up to day 28 of life [14].

4. Another recent randomised double-blind controlled trial is a single centre trial on 207 premature neonates less than 34 weeks of gestation to iNO 10 ppm on the first day followed by 5 ppm for 6 days or inhaled oxygen placebo for 7 days. The authors reported a lower incidence of death or chronic lung disease in the group given inhaled nitric oxide (48.6% vs 63.7%, RR 0.76; 95% CI 0.60–0.97; P = 0.03), as well as a lower incidence of severe IVH and PVL (12.4% vs 23.5%; RR 0.53, 95% CI 0.28–0.98; P = 0.04). This is the only trial which has shown a beneficial role of inhaled nitric oxide in preterm neonates.

However, the major concerns regarding this trial are that the placebo group had very high mortality (63.7% vs 48.6) and the use of antenatal steroids is only about 50%. Also, the enrolled neonates were much less sick than those in other trials (median OI 6.94) [15]. The authors have also published their data on 138 children followed up longitudinally till 2 years corrected age. Inhaled nitric oxide group were shown to have significantly less abnormal neurodevelopmental outcomes (24% vs 46%; RR, 0.53; 95% of CI 0.33–0.87; p = 0.01). This difference was independent of birthweight, sex, presence or absence of chronic lung disease (CLD) and severe IVH or PVL. This improvement was shown primarily due to a 47% decrease in the risk of cognitive impairment (p = 0.03) [16].

5. There are three other small randomised trials for which pooled meta-analysis of 210 infants <33 weeks of gestation did not reveal any difference in death (39.6% iNO vs 40.4%, p = 0.91), death or CLD (OR 0.77, 95% CI 0.41–1.45; p = 0.39) or IVH (OR 1.37, 95% CI 0.69–2.74; P = 0.33) [9].

A preliminary meta-analysis of all available studies of iNO in preterm infants published up to March 2005 suggested that although iNO may reduce death or BPD at 36 weeks postconceptional age, there may be an increase in the occurrence of severe IVH or PVL [20]. Pathophysiologica aspects of inhaled nitric oxide on the developing central nervous system are not clear [21, 22]. Furthermore, some animal model studies have shown a beneficial effect of low doses of nitric oxide given for weeks on the development of respiratory system including effects on angiogenesis, maturation of lung parenchyma and airway smooth muscle [23].

Conclusions

Uncertainty surrounds the use of inhaled nitric oxide in preterm neonates. There is no evidence to recommend the routine rescue use of inhaled nitric oxide in preterm infants with hypoxaemic respiratory failure. Pre-treatment oxygenation index and timing may be factors determining whether inhaled nitric oxide will produce beneficial results. Examining the evidence and the prohibitive costs of inhaled nitric oxide, it does not seem to be a feasible option for the introduction of iNO in developing nations.

References

The diabetes epidemic in Sri Lanka – a growing problem

P Katulanda¹, ², MHR Sheriff² and DR Matthews²

Abstract
Diabetes mellitus, which was once considered a disease of the developed world, has become a worldwide pandemic, with two thirds of the global diabetic population living in the developing countries. Local studies show a definite upward trend in the prevalence of diabetes mellitus. The earliest available study on a rural community in 1990 reported a prevalence of 2.5%. The largest-ever study on the diabetes prevalence in Sri Lanka was published in 2005. It showed a prevalence of 14.2% among males and 13.5% among females.

The World Health Organisation and the International Diabetic Federation estimates and forecasts are much lower than the available local prevalence rates, and what may be predicted from the prevalence rates in South India. Further research is necessary to investigate the exact underlying mechanisms for the South Asian epidemic. Wider preventive programmes need to be urgently implemented to stem the tide.

Introduction
The world is facing a pandemic of diabetes mellitus, affecting both developed and developing countries [1–3]. By 2025, south east Asia is expected to be the region with the highest number of diabetic patients in the world [3]. Accurate figures of the prevalence of diabetes mellitus are needed for planning primary prevention programmes and secondary and tertiary care.

Diabetes prevalence in Sri Lanka
Several investigators have estimated the prevalence of diabetes mellitus in Sri Lanka over the last 15 years [4–9]. Most of the studies were on rural or suburban populations. The sample sizes varied between 220 and 6047. The criteria used to diagnose diabetes mellitus were different between studies. Fasting blood glucose was used in some studies, and the oral glucose tolerance test in others. The earlier studies have used the 1985 WHO criteria [10], and the newer studies used the 1997 American Diabetic Association (ADA) criteria [11] for diagnosis. The available studies show a definite upward trend in the prevalence of diabetes mellitus in Sri Lanka (Table 1).

A study done in 1990 [4] on a rural community using the oral glucose tolerance test and the 1985 WHO criteria for diagnosis reported a prevalence of 2.5%. There were two studies published in 1994. One study [5] on a suburban community using the 1985 WHO criteria showed a prevalence of 5.02% and the other study [6] on a mixed population using fasting blood glucose according to the 1985 WHO criteria indicated a prevalence of 5.87%. These